MARIMED INC.: management transactions · United States · SEC (Form 4)

About MARIMED INC.

MariMed Inc. is a U.S.-based cannabis operator headquartered in Norwood, Massachusetts, with public-market disclosure and communications tied to the U.S. market and a trading presence referenced in Nasdaq coverage; its securities are also quoted on OTCQX. For investors, the company should be viewed primarily as a multi-state cannabis consumer and brand platform rather than a pure cultivation story. MariMed develops, owns, and manages state-licensed, seed-to-sale facilities for the cultivation, production, and dispensing of medical and adult-use cannabis across the United States. Its model spans retail, wholesale, and brand licensing, giving it multiple revenue channels and a way to expand brand reach beyond company-owned stores. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000014/mrmd-20241231.htm?utm_source=openai)) Historically, the company has evolved from a broader management-oriented cannabis platform into a more focused branded consumer-products strategy. SEC filings show a gradual buildout of owned facilities, licenses, and distribution capabilities, reflecting a long-term effort to create a more scalable, vertically integrated business. MariMed’s principal executive offices are located at 10 Oceana Way in Norwood, Massachusetts. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000014/mrmd-20241231.htm?utm_source=openai)) MariMed’s core business lines include cultivation, processing, retail dispensary operations, wholesale distribution, and intellectual-property monetization through product licensing. The company’s branded portfolio includes Nature’s Heritage, Betty’s Eddies, Kalm Fusion, Bubby’s Baked, Vibations, and InHouse. These brands cover premium flower, concentrates, edibles, fruit chews, chewable tablets, drink mixes, and other precisely dosed cannabis products. The strategic emphasis is on premium consumer packaged goods with repeat purchasing potential, which is a key differentiator in a fragmented and highly regulated market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000014/mrmd-20241231.htm?utm_source=openai)) In competitive terms, MariMed is positioned as a focused niche operator in a sector dominated by larger multi-state peers. Rather than competing only on cultivation scale, it aims to win through brand strength, product quality, and wholesale penetration. Management has said the company’s “Expand the Brand” strategy is intended to grow share in core markets and extend distribution into higher-growth states. That approach can be attractive for investors seeking exposure to branded cannabis products, but it also leaves the company exposed to pricing pressure and regulatory complexity in the wider U.S. cannabis market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000167/marimedq22025ex991.htm?utm_source=openai)) Recent developments are important for the investment case. In 2025, MariMed reported revenue growth, its sixth consecutive year of positive Adjusted EBITDA, and expanded distribution across a large portion of dispensaries in its core markets. It also highlighted new agreements intended to broaden the reach of its brands into Maine, Pennsylvania, and New York. In March 2026, the company reported its 2025 full-year results and said it had exited Missouri after a strategic review, signaling a more disciplined capital allocation approach and a focus on higher-return markets. ([nasdaq.com](https://www.nasdaq.com/press-release/marimed-reports-fourth-quarter-and-full-year-2025-earnings-2026-03-11?utm_source=openai))